A comprehensive portfolio of psychedelic therapeutic programs targeting neurological and psychiatric disorders. Each program represents our commitment to developing innovative treatments for patients in need. Our platform supports the development of novel neurotherapeutic candidates, including research into next-generation compounds inspired by established psychedelic scaffolds such as ibogaine analogs—with a focus on improving safety, scalability, and clinical viability.
Platform-driven innovation with multi-layered intellectual property protection across discovery, therapeutic development, and delivery systems. Our research includes ibogaine-inspired molecular frameworks designed to improve safety profiles and clinical viability for next-generation neurotherapeutics.
Core molecule generation
Drug candidates
Scalable administration
Global supply chain
Commercial expansion
Next Gen 5-HT2A Receptor Agonists
→ 40 Tryptamine Molecules
Target: Next-gen psychiatric therapeutics
→ Feeds HUX-001 / HUX-002
Non-hallucinogenic Proprietary Tryptamines
Target: Neuroplasticity without psychedelic effects
← From HUX-004
2 programs
Non-phosphorylated Tryptamine
→ Psilocin, Antioxidant
Target: TNF-α induced inflammatory disease
← Delivery-supported
Tryptamines & MAOIs Combination
→ Psilocin, β-Carboline
Target: Combination psychedelic therapy
← Delivery-supported
Controlled Release Delivery System
→ Psilocin, Polymeric Spheres
Role: Therapeutic innovation layer
Non-hallucinogenic Tryptamine Compounds
→ Pegylated Psilocin
Target: Neuroplastic benefits without psychedelic effects
→ Feeds HUX-008
Lipidic Nano-Pharmaceuticals
→ Psilocin, β-Carboline
Role: Therapeutic innovation layer
5 programs
Scalable & controllable psychedelic therapies
Cost-advantaged global supply chain
Adjacent Therapeutic Expansion
Category: Consumer & wellness markets
← Platform-enabled
Optionality
Core molecules feed drug candidates
Direct pathway to expansion
Vertical IP protection layer
Strategic moat architecture showing competitive advantages
MOAT
Foundational chemistry, synthesis pathways, and compound scalability
Adjacent Therapeutic Expansion
Consumer & wellness markets
Delivery IP - Synthesis Pathway
Manufacturing IP - Synthesis
Delivery IP - Synthesis Optimization
MOAT
Delivery systems enabling precision dosing, bioavailability, and control
Controlled Release Delivery
Lipidic Nano-Pharmaceuticals
Manufacturing - Nano Scale
Delivery IP - Formulation
Delivery IP - Bioavailability
Delivery IP - Precision
Delivery IP - Control
Delivery IP - Novel Systems
Manufacturing - Scale-up
MOAT
Core drug innovation including novel compounds and non-hallucinogenic therapeutics
Non-phosphorylated Tryptamine
TNF-α inflammatory disease
Tryptamines & MAOIs Combination
Combination psychedelic therapy
Non-hallucinogenic Tryptamines
Neuroplastic benefits
5-HT2A Receptor Agonists
40 Tryptamine Molecules
Non-hallucinogenic Tryptamines
Neuroplasticity without effects
Manufacturing - Compound
4 programs
9 programs
6 programs
Psilocin, Antioxidant
Target
TNF-α induced inflammatory disease
Psilocin, B-Carboline
Target
Combination psychedelic therapy
Psilocin, Polymeric Spheres
Target
Sustained exposure, improved dosing
Pegylated Psilocin
Target
Neuroplastic benefits without psychedelic effects
40 Tryptamine Molecules
Target
Next-gen psychiatric therapeutics
Psilocin, B-Carboline
Target
Improved pharmacokinetics & safety
Psilocin, Polymeric Spheres
Target
Improved oral bioavailability
Proprietary non-hallucinogenic tryptamines
Target
Neuroplasticity without psychedelic effects
A foundational capability supporting long-term pipeline expansion by addressing one of the industry's most critical structural challenges.
Ibogaine Synthesis & Manufacturing Infrastructure
Huxley Health, through its Aerasyn Biotech division, is advancing what it believes is one of a very limited number of synthesis and manufacturing-focused patent initiatives globally targeting ibogaine at scale. This work reflects an extended internal R&D effort and supports the company's belief that control over scalable supply infrastructure may become as important as clinical development itself as the sector matures.
While clinical and academic research continues to explore ibogaine's potential in addiction and neuropsychiatric disorders, the broader industry remains constrained by limited supply, non-scalable production, complex synthesis pathways, and reproducibility challenges.
These developments reflect a streamlined effort to align Huxley Health's scientific platform, leadership bench, and corporate structure as the company advances toward a broader public market strategy.
Two expected provisional patents focused on ibogaine synthesis and manufacturing
Addresses supply limitations and production complexity
Supports reproducibility, scale, and cost efficiency
Reinforces IP- and platform-driven biotech positioning
Preclinical / Patent Filing Stage
2
Provisional Patents
1
Global Initiative
24/7
Platform Development
"Huxley believes that scalable manufacturing and supply control may become defining advantages in the next phase of neurotherapeutic innovation."
Infrastructure as Competitive Moat